Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 5Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 5Neuroendocrine Tumors 2Gastro-enteropancreatic neuroendocrine tumor 2Digestive System Neoplasms 2Urogenital Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Diseases 1Prostate Cancer Metastatic 1Pancreatic Neoplasms 1Pancreatic Diseases 1Neuroectodermal Tumors 1Neoplasms, Nerve Tissue 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Metastatic Castration-Resistant Prostate Cancer 1Lung Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Digestive System Diseases 1Breast Neoplasms 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

Magnetic Resonance Spectroscopy 51Specimen Handling 42enzalutamide 35Androgen Antagonists 34Radiosurgery 32Radiotherapy 31Prednisone 26darolutamide 24Abiraterone Acetate 24Leuprolide 22Docetaxel 22apalutamide 20Pluvicto 19abiraterone 18Standard of Care 18Triptorelin Pamoate 17Radiation 17Biopsy 16relugolix 15acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Goserelin 14Blood Specimen Collection 13gallium 68 PSMA-11 12pembrolizumab 11X-Rays 11Surveys and Questionnaires 11luprolide acetate gel depot 10Carboplatin 10Methods 9Interviews as Topic 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Prostatic Neoplasms × Lutetium × Clear all
NCT06520345 2026-05-27

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3 Recruiting
520 enrolled
Genitourinary

Prostatic Neoplasms

NCT05413850 2026-05-14

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Blue Earth Therapeutics Ltd

Phase 1/2 Recruiting
82 enrolled
Genitourinary

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT06517719 2026-04-13

Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

Novartis

Recruiting
500 enrolled
Genitourinary

Prostatic Neoplasms

NCT05803941 2025-04-24

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Novartis

Phase 4 Recruiting
700 enrolled
Genitourinary

Prostatic Neoplasms

NCT06449781 2025-02-10

PSMA-ADJUVO

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 2 Recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡